Third Quarter 2023 Financial and Business Update November 8, 2023 DISCLAIMERS Forward-Looking Statements This presenta,on contains “forward-looking statements” within the meaning of the Private Securi,es Li,ga,on Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expecta,ons and assump,ons regarding the future of our business, future plans and strategies, our clinical results and other future condi ...

Financial Data and Key Metrics Changes - As of September 30, 2023, the company reported cash and cash equivalents of $595.1 million, with a cash runway extending well into 2026 [10][23]. - General and administrative expenses remained consistent year-over-year, while research and development expenses increased due to advancements in COVID-19 and HCV clinical programs [23]. Business Line Data and Key Metrics Changes - The COVID-19 program is progressing well, with enrollment in the SUNRISE-3 trial reflecting global infection rates and a strong patient enrollment trend, particularly in the U.S. [7][13]. - The HCV program has completed enrollment of the 60-patient leading cohort in its Phase II combination study of bemnifosbuvir and ruzasvir, with initial results expected in early 2024 [10][20]. Market Data and Key Metrics Changes - The U.S. market for COVID-19 oral antivirals is projected to be a multibillion-dollar opportunity, with an estimated annual global market of approximately $10 billion [18]. - The global net sales market for hepatitis C was approximately $3.5 billion in 2022, with the U.S. representing roughly 50% of that market [47]. Company Strategy and Development Direction - The company aims to deliver effective treatments for COVID-19 and HCV, addressing unmet medical needs with a focus on safety and tolerability [8][10]. - Atea Pharmaceuticals is pursuing a multipronged approach against COVID-19, including the development of a second-generation protease inhibitor [9]. Management's Comments on Operating Environment and Future Outlook - Management highlighted the ongoing evolution of COVID-19 variants and the urgent need for new oral antivirals, emphasizing the potential of bemnifosbuvir to address current treatment limitations [12][13]. - The company anticipates that 2024 will be transformational, with several key data readouts expected [24]. Other Important Information - The company has received fast track designation for bemnifosbuvir, reflecting the recognized unmet medical need for COVID-19 patients [16]. - Atea plans to present supportive data for bemnifosbuvir and ruzasvir at the 2023 Annual Meeting of the American Association for the Study of Liver Diseases [22]. Q&A Session Summary Question: Enrollment pace and interim analysis for SUNRISE-3 - Management confirmed that the first interim analysis is on track for Q1 2024 and emphasized confidence in enrollment pace due to a broad geographical footprint [28][30]. Question: Context of SUNRISE-3 in competitive landscape - Management believes hospitalization is the most important benefit and highlighted differences in trial populations compared to competitors [35][37]. Question: Efficacy communication timeline for SUNRISE-3 - Management indicated that the unpredictable nature of COVID surges makes it difficult to estimate when efficacy data could be communicated [40]. Question: Interim DSMB analysis announcement - Management stated that the announcement will confirm whether the study can continue or not, without providing initial safety data [52].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR (Stat ...

Second Quarter 2023 Financial and Business Update August 8, 2023 DISCLAIMERS Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Jonae Barnes – Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi – Chief Executive Officer and Founder Janet Hammond – Chief Development Officer Arantxa Horga – Chief Medical Officer Andrea Corcoran – Chief Financial Officer and Executive Vice President of Legal John Vavricka – Chief Commercial Officer Conference Call Participants Maxwell Skor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 4 ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder and Chief Executive Officer Andrea Corcoran - Financial Officer and Executive Vice President of Legal Janet Hammond - Chief Development Officer Conference Call Participants Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Tim Lugo - William Blair Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Jonae Barnes - Senior VP, Investor Relations & Corporate Communications Jean Sommadossi - Founder, Chairman & CEO Andrea Corcoran - CFO & Executive VP, Legal Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Conference Call Participants Roanna Ruiz - SVB Leerink Jessica Hui - Evercore Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its Charter) Delaware 46-0574869 (State or other jurisdict ...